Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials

Currently viewing trials
(Last updated: February 22, 2020)

Zip Code:

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 



Hormone Therapy

Radiation Oncology


Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment



Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children


Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence





NEAREST SITE: 1643 miles
Kymab investigator site 1101

VISITS: Number of visits unavailable


NCT ID: NCT03829501

KY1044 and Atezolizumab Immunotherapy for Advanced Triple Negative Breast Cancer

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies Scientific Title

To study the safety and the effects (good and bad) of using KY1044 alone or with Tecentriq® (atezolizumab) to treat advanced breast cancer.
Who is this for?
People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-/PR-/HER2-) breast cancer that has not responded to other treatment options.    Full eligibility criteria
Contact research site

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will be assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Monotherapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">KY1044</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Combination Therapy</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">KY1044</li> <li class="seamTextUnorderedListItem">Atezolizumab (Tecentriq®), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site for treatment schedule</i></p>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">KY1044 stimulates immune cells to go after and kill cancer cells. </li> <li class="seamTextUnorderedListItem">It also kills the T regulatory cells that keep immune cells from killing the cancer cells.</li> <li class="seamTextUnorderedListItem">Tecentriq® (atezolizumab) is a type of immunotherapy called a PD-L1 (programmed cell death-ligand 1) inhibitor. </li> <li class="seamTextUnorderedListItem">It is approved to treat advanced triple negative breast cancer, as well as certain types of bladder and lung cancer.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03829501' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.statnews.com/2019/03/08/roche-tecentriq-first-breast-cancer-immunotherapy/' target='_blank'>StatNews: Tecentriq approval for breast cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.kymab.com/news-and-events/news/2017/nov/8/ky1044-anti-icos-antibody-sitc/' target='_blank'>Drug Sponsor Site: KY1044</a> </li></ul>
See more